The phytochemical arbutin exerts potent anti-Toxoplasma effects through activation of cell-autonomous defense mechanisms while attenuating inflammation
Open Access
- 11 December 2025
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 19 (12) , e0013815
Abstract
Background: Plant-derived natural products have emerged as promising candidates for developing novel anti-toxoplasmosis drugs. This study aimed to elucidate the role and mechanism of the phytochemical arbutin in the control of T. gondii infection. Methodology/Principal findings: The effect of arbutin on T. gondii infection and host inflammatory response was evaluated both in vitro and in vivo. RNA-seq was performed on mouse bone marrow-derived macrophage samples to identify potential arbutin-related biological processes and molecular targets that control T. gondii infection. These targets were further confirmed using target-specific activators or inhibitors. Our data indicated that arbutin has dual therapeutic effects against T. gondii infection through concurrently controlling parasite growth and mitigating infection-induced inflammation. Mechanistically, arbutin mediates restriction of intracellular labile iron pool in both immune and non-immune cells, thereby depriving the parasite of essential metal nutrients. In addition, in macrophages, arbutin not only inhibits infection-induced inflammatory response but also upregulates the expression of heme degrading enzyme heme oxygenase-1, which facilitates biliverdin production. Our data further demonstrated that biliverdin exhibits anti- T. gondii effector function. Furthermore, arbutin is also effective in reducing infection-related mortality in immunocompromised mice. Conclusions/Significance: Our data highlight arbutin’s potential therapeutic value in fighting against acute hyperinflammatory phase of Toxoplasmosis even in immunocompromised host but also its limitation in establishing long-term immunity. Our study further suggests a potential direction for further development of effective drugs to prevent and treat toxoplasmosis by pharmacologically enhancing cell-autonomous defense mechanisms while suppressing inflammatory response.Keywords
Funding Information
- National Natural Science Foundation of China (82471850)
- National Natural Science Foundation of China (82002157)
- Xuzhou Medical University (JBGS202202)
- Jiangsu Provincial Government Scholarship for Overseas Study Funding
- Xuzhou Medical University (2024BMS28)
This publication has 30 references indexed in Scilit:
- Comprehensive Insights into the Development of Antitoxoplasmosis Drugs: Current Advances, Obstacles, and Future PerspectivesJournal of Medicinal Chemistry, 2024
- Examining Hemin and its Derivatives: Induction of Heme-Oxygenase-1 Activity and Oxidative Stress in Breast Cancer Cells through Collaborative Experimental Analysis and Molecular Dynamics SimulationsJournal of Medicinal Chemistry, 2024
- Anti-Toxoplasma In Vitro and In Vivo Activity of Pyrus boissieriana Arbutin-Rich FractionActa Parasitologica, 2024
- Biliverdin as a disease-modifying agent: An integrated viewpointFree Radical Biology and Medicine, 2023
- The vacuolar iron transporter mediates iron detoxification in Toxoplasma gondiiNature Communications, 2023
- Anti-Toxoplasma gondii agent isolated from Orostachys malacophylla (Pallas) FischerExperimental Parasitology, 2022
- Infections at the maternal–fetal interface: an overview of pathogenesis and defenceNature Reviews Microbiology, 2021
- Induction of indoleamine 2,3-dioxygenase expression via heme oxygenase-1-dependant pathway during murine dendritic cell maturationBiochemical Pharmacology, 2010
- Toxoplasma gondii infection in humans and animals in the United StatesInternational Journal for Parasitology, 2008
- IL-4 and IL-13 regulate the induction of indoleamine 2,3-dioxygenase activity and the control ofToxoplasma gondii replication in human fibroblasts activated with IFN-γEuropean Journal of Immunology, 2001